Published • loading... • Updated
Drug From Stony Brook-Developed Anti-Cancer Compounds Now in Clinical Trials
Summary by Newswise
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Drug From Stony Brook-Developed Anti-Cancer Compounds Now in Clinical Trials
A promising new cancer chemotherapeutic agent from a taxane class of natural compounds – anti-cancer agents designed to block cell division and trigger the programmed cell death to treat sold tumors – originally developed by researchers at Stony Brook University has entered human clinical trials.
·Charlottesville, United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
